Tortugas Neuroscience
Stub active Updated Apr 25, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
About
Tortugas Neuroscience is a Framingham, Massachusetts-based clinical-stage biopharmaceutical company developing novel medicines for neurology and neuropsychiatric disorders 12. Founded by CEO Jeff Jonas, M.D. and President Al Robichaud, Ph.D., both veterans of Sage Therapeutics, the company in-licensed its clinical pipeline from Eisai (Japan) and Jiangsu Hansoh Pharmaceutical (Greater China) 12. Programs target schizophrenia, tinnitus, focal epilepsy, and reversible encephalopathies 1.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-04-21 | Seed + Series A (combined) | $106M | Cure Ventures (Seed lead, Series A co-lead) | The Column Group, AN Venture Partners 123 |
What Investors Say
No independently sourced investor quotes found.
What Founders Say
No independently sourced founder quotes found.
Sources
-
BioSpace, “Tortugas Neuroscience Launches with $106 Million to Advance Clinical Stage Pipeline Targeting New and Major Neurology and Neuropsychiatric Disorders,” April 21, 2026. https://www.biospace.com/press-releases/tortugas-neuroscience-launches-with-106-million-to-advance-clinical-stage-pipeline-targeting-new-and-major-neurology-and-neuropsychiatric-disorders↩↩↩↩
-
BusinessWire, “Tortugas Neuroscience Launches with $106 Million to Advance Clinical Stage Pipeline Targeting New and Major Neurology and Neuropsychiatric Disorders,” April 21, 2026. https://www.businesswire.com/news/home/20260421372757/en/Tortugas-Neuroscience-Launches-with-$106-Million-to-Advance-Clinical-Stage-Pipeline-Targeting-New-and-Major-Neurology-and-Neuropsychiatric-Disorders↩↩↩
-
BioPharma Dive, “Tortugas debuts with $106M and brain drugs from Hansoh, Eisai,” April 21, 2026. https://www.biopharmadive.com/news/tortugas-biotech-startup-jonas-robichaud-hansoh-eisai/818076/↩